5Castellsague X,de Sanjose S,Aguado T,et al.HPV and cervical cancer in the world 2007 report[J].Vaccine,2007,25(15):2749-2958.
6Lynette Denny.Cervical cancer prevention:New opportunities for primary and secondary prevention in the 21st century[J].International Journal of Gynecology and Obstetrics,2012,119:80-84.
7Helen Dinkelspiel,Barbara Fetterman,Nancy Poitras,et al.Screening history preceding a diagnosis of cervical cancer in women age 65 and older[J].Gynecologic Oncology,2012,126:203-206.
8Thomas C,Wright Jr,Louise Kuhn,et al.Alternative approaches to cervical cancer screening for developing countries[J].Best Practice & Research Clinical Obstetrics and Gynaecology,2012,26:197-208.
10Castle PE,Stoler MH,Wright Jr.et al.Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 orHPV18 genotyping for cervical cancer screening of women aged 25 years and older:a subanalysis of the ATHENA study[J].Lancet Oncol,2011,12:880-890.
7Segawa T, Sasagawa T, Yamazaki H, et al. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma [ J ]. Cancer, 1999,85 (9) :2001-2010.
8Bulk S, Berkhof J, Bulkmans N W, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV 18 for ad- enocarcinoma of the cervix compared to women with normal cytology in the Netherlans[ J]. Br J Cancer,2006,94 (1) : 171-175.
9段华.宫颈癌早期无明显症状[N].人民日报,2011-11-24(19).
10Vandecasteele K,Makar A,Van den Broecke R,et al.Intensity modulated arc therapy with eisplatin as neoaaiuvant treatment for primary irresectablecervical cancer.Toxicity,tumour response and outcome[J].Strahlenther Onkol,2012,188(7):576.
